Personalized mRNA Vaccine Paired with Keytruda Shows Promise Against Melanoma Recurrence
核心洞察
A personalized mRNA vaccine combined with the immunotherapy drug Keytruda reduced the likelihood of melanoma (搜索) returning or spreading compared with Keytruda alone, according to early clinical trial data.
Merck (搜索) and Moderna tested the combination in melanoma (搜索) patients whose tumors had been surgically removed, with the vaccine tailored to each individual's tumor.
Dr. Michael Postow, a medical oncologist at Memorial Sloan Kettering Cancer Center involved in the trial, described the treatment as promising.
A promising new skin cancer vaccine could help keep melanoma (搜索) — the deadliest form of skin cancer — from coming back or spreading to other parts of the body, according to early data from a clinical trial. The treatment pairs a personalized mRNA vaccine with the immunotherapy drug Keytruda in patients whose tumors had been surgically removed.
Merck (搜索) and Moderna tested the combination in melanoma (搜索) patients who had undergone surgical removal of their tumors. Patients given the combination treatment were less likely to have the cancer return or spread compared to those who received Keytruda alone.
Dr. Michael Postow, a medical oncologist at Memorial Sloan Kettering Cancer Center who was involved in the trial, spoke about what makes the treatment so promising. The vaccine is not specific to melanoma (搜索) — it is tailored to each person's tumor — so in theory, the same approach could tackle other tumors as well.
The potential of this groundbreaking treatment extends beyond skin cancer. Because the vaccine is personalized to each individual's tumor rather than being melanoma (搜索)-specific, researchers suggest the same approach could be applied to other tumor types, broadening the therapeutic implications of this strategy.